biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sir_Holleron Jun 15, 2015 2:38pm

112 Views

Post# 23832173

RE:RE:RE:ok,here's what i think

This last 1 1/2 years has been a time of transition to Transcendpep.

Now we get to see what we've been waiting for as the data will soon be released, even published.
This is an important time for the programs and the platform.
This paves the way for human testing.
Since we already know that if BTI can deliver to the human brain its two lead programs should work it won't take much human data to support success.

The next year-and-half will not be like the last and will go a long way to derisking the platform.

Bullboard Posts

Who, why, and what of the great "Crypto Surge"